Federal Court Strikes Down FDA Rule on LDTs

Описание: On March 31, 2025, the U.S. District Court for the Eastern District of Texas ruled that the Food and Drug Administration (FDA) lacks the statutory authority to regulate laboratory-developed tests (LDTs).

The court’s judgment vacates the agency’s controversial final rule of May 6, 2024 (the “Final Rule”), regulating LDTs as medical devices, just weeks before the Final Rule’s initial implementation deadline and remands the issue back to the FDA for further consideration.

Key Takeaways
1.) Implementation of the Final Rule would have imposed major burdens on many laboratories that will now no longer apply.
2.) Manufacturers and distributors of laboratory reagents and equipment may be subject to FDA enforcement.
3.) The FDA and the Centers for Medicare & Medicaid Services have collaborated to align their roles in the regulation of LDTs, as highlighted in their joint statement.
4.) Despite recent developments, questions persist regarding whether updates or revisions to the current regulatory framework for LDTs will be issued.
5.) Any regulatory updates could have significant implications for stakeholders in the diagnostics and health care sectors, emphasizing the need for continued vigilance and compliance. Epstein Becker Green is dedicated to keeping clients informed and equipped to navigate potential changes in the regulatory landscape for LDTs.

For more information on the Final Rule, visit https://www.ebglaw.com/insights/publi....

The Thought Leaders in Health Law® video series tracks the latest trends in multiple areas of the health care and life sciences industries, featuring attorneys and advisors from Epstein Becker Green and EBG Advisors.

These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. THOUGHT LEADERS IN HEALTH LAW® is a registered trademark of Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.